The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Open accessPublished version of a preprint
Abstract
Defenses against SARS-CoV-2 variants: Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Self-citationTowards automated crystallographic structure refinement with phenix.refine
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J., Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev, A., Zwart, P. H., & Adams, P. D. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912001308 · Cited by 5,511
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Self-citationConvergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Research works printed but not linked: 24
- 10.1126/science.abd0826 · DOI · Paper page
- 10.1016/j.celrep.2020.108322 · DOI
- 10.1016/j.cell.2020.05.042 · DOI · Paper page
- 10.1126/scitranslmed.abf1906 · DOI · Paper page
- 10.1038/s41586-020-2349-y · DOI · Paper page
- 10.1016/j.cell.2021.01.037 · DOI · Paper page
- 10.1038/s41586-020-2381-y · DOI · Paper page
- 10.1016/j.chom.2020.06.020 · DOI · Paper page
- 10.1126/science.abf4830 · DOI · Paper page
- 10.1016/j.chom.2021.03.002 · DOI · Paper page
- 10.1016/j.immuni.2019.02.008 · DOI
- 10.1186/s13073-018-0528-3 · DOI
- 10.3389/fimmu.2016.00372 · DOI
- 10.1126/science.aad6117 · DOI · Paper page
- 10.1128/JVI.79.14.8828-8834.2005 · DOI · Paper page
- 10.1016/j.vaccine.2007.02.050 · DOI
- 10.1073/pnas.93.21.11382 · DOI · Paper page
- 10.1073/pnas.0409065102 · DOI · Paper page
- 10.1038/ncomms8712 · DOI · Paper page
- 10.1038/nmeth.4169 · DOI · Paper page
- 10.1107/S0907444904019158 · DOI · Paper page
- 10.1093/nar/gkh398 · DOI · Paper page
- 10.1002/jcc.20084 · DOI · Paper page
- 10.1093/infdis/jiy071 · doi:10.1093/infdis/jiy071
Cited by
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527
Self-citationMapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 414
Self-citationStructural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364
Improved AlphaFold modeling with implicit experimental information
Terwilliger, T. C., Poon, B. K., Afonine, P. V., Schlicksup, C. J., Croll, T. I., Millán, C., Richardson, J. S., Read, R. J., & Adams, P. D. (2022) · Nature Methods · doi:10.1038/s41592-022-01645-6 · Cited by 140
Metadata
- Authors
- Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S., Narpala, S. R., Hatcher, C., Martinez, D. R., Tsybovsky, Y., Phung, E., Abiona, O. M., Antia, A., Cale, E. M., Chang, L. A., Choe, M., Corbett, K. S., Davis, R. L., DiPiazza, A. T., Gordon, I. J., Hait, S. H., Hermanus, T., Kgagudi, P., Laboune, F., Leung, K., Liu, T., Mason, R. D., Nazzari, A. F., Novik, L., O’Connell, S., O’Dell, S., Olia, A. S., Schmidt, S. D., Stephens, T., Stringham, C. D., Talana, C. A., Teng, I.-T., Wagner, D. A., Widge, A. T., Zhang, B., Roederer, M., Ledgerwood, J. E., Ruckwardt, T. J., Gaudinski, M. R., Moore, P. L., Doria-Rose, N. A., Baric, R. S., Graham, B. S., McDermott, A. B., Douek, D. C., Kwong, P. D., Mascola, J. R., Sullivan, N. J., & Misasi, J.
- Venue
- Science
- Published
- 2021-08-13
- Volume
- 373
- Issue
- 6556
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3175183123
- Cited by
- 206
- References
- 24
- FWCI
- 14.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Institutes of Health (NIH NIAID T32 AI007151, NIH F32 AI152296, NIH RO1 AI157155)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. https://app.cochat.ai/papers/10.1126/science.abh1766
- The paper
- Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S., Narpala, S. R., Hatcher, C., Martinez, D. R., Tsybovsky, Y., Phung, E., Abiona, O. M., Antia, A., Cale, E. M., Chang, L. A., . . . Misasi, J. (2021). Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. https://doi.org/10.1126/science.abh1766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.